$131.03
Revenue is up for the last 2 quarters, 892.81M → 957.31M (in $), with an average increase of 6.7% per quarter
Netprofit is up for the last 3 quarters, -240.72M → 104.43M (in $), with an average increase of 240.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 84.6% return, outperforming this stock by 82.8%
In the last 3 years, Novo Nordisk A/s has given 165.1% return, outperforming this stock by 172.4%
0.12%
Downside
Day's Volatility :1.17%
Upside
1.05%
7.93%
Downside
52 Weeks Volatility :25.05%
Upside
18.59%
Period | Jazz Pharmaceuticals Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 7.13% | -1.1% | 0.0% |
6 Months | -7.97% | 1.6% | 0.9% |
1 Year | 1.78% | 4.2% | 3.1% |
3 Years | -7.25% | 24.2% | 17.1% |
Market Capitalization | 8.4B |
Book Value | $55.61 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.61 |
PEG Ratio | 3.99 |
Wall Street Target Price | 201.06 |
Profit Margin | -2.3% |
Operating Margin TTM | 26.8% |
Return On Assets TTM | 5.61% |
Return On Equity TTM | -2.57% |
Revenue TTM | 3.8B |
Revenue Per Share TTM | 59.41 |
Quarterly Revenue Growth YOY | 2.6% |
Gross Profit TTM | 3.4B |
EBITDA | 1.6B |
Diluted Eps TTM | -1.61 |
Quarterly Earnings Growth YOY | 1.76 |
EPS Estimate Current Year | 18.59 |
EPS Estimate Next Year | 20.17 |
EPS Estimate Current Quarter | 4.43 |
EPS Estimate Next Quarter | 4.56 |
What analysts predicted
Upside of 53.45%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↑ 8.79% |
Net Income | 487.8M | ↑ 22.94% |
Net Profit Margin | 30.14% | ↑ 3.47% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 16.82% |
Net Income | 447.1M | ↓ 8.35% |
Net Profit Margin | 23.64% | ↓ 6.5% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↑ 14.32% |
Net Income | 523.4M | ↑ 17.06% |
Net Profit Margin | 24.21% | ↑ 0.57% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.4B | ↑ 9.34% |
Net Income | 238.6M | ↓ 54.41% |
Net Profit Margin | 10.1% | ↓ 14.11% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.1B | ↑ 30.91% |
Net Income | -329.7M | ↓ 238.16% |
Net Profit Margin | -10.65% | ↓ 20.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | ↑ 18.26% |
Net Income | -531.4M | ↑ 61.2% |
Net Profit Margin | -14.52% | ↓ 3.87% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 813.7M | ↓ 9.26% |
Net Income | 1.6M | ↓ 104.66% |
Net Profit Margin | 0.2% | ↑ 4.14% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 932.9M | ↑ 14.64% |
Net Income | 34.7M | ↑ 2004.74% |
Net Profit Margin | 3.72% | ↑ 3.52% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 940.7M | ↑ 0.83% |
Net Income | -19.6M | ↓ 156.68% |
Net Profit Margin | -2.09% | ↓ 5.81% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 972.1M | ↑ 3.35% |
Net Income | -240.7M | ↑ 1125.18% |
Net Profit Margin | -24.76% | ↓ 22.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 892.8M | ↓ 8.16% |
Net Income | 69.4M | ↓ 128.84% |
Net Profit Margin | 7.78% | ↑ 32.54% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 957.3M | ↑ 7.22% |
Net Income | 104.4M | ↑ 50.44% |
Net Profit Margin | 10.91% | ↑ 3.13% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 5.1B | ↑ 6.74% |
Total Liabilities | 2.4B | ↓ 17.53% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 5.2B | ↑ 1.56% |
Total Liabilities | 2.4B | ↑ 1.47% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 5.5B | ↑ 6.45% |
Total Liabilities | 2.4B | ↓ 0.74% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↑ 18.0% |
Total Liabilities | 2.9B | ↑ 18.46% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 12.3B | ↑ 88.17% |
Total Liabilities | 8.3B | ↑ 189.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↓ 11.9% |
Total Liabilities | 7.7B | ↓ 7.01% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.8B | ↓ 4.31% |
Total Liabilities | 8.2B | ↓ 2.08% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.2B | ↓ 4.83% |
Total Liabilities | 8.0B | ↓ 1.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.4B | ↓ 7.28% |
Total Liabilities | 7.6B | ↓ 4.5% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↑ 4.34% |
Total Liabilities | 7.7B | ↑ 1.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 1.96% |
Total Liabilities | 7.6B | ↓ 1.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.3B | ↑ 1.93% |
Total Liabilities | 7.7B | ↑ 1.24% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 693.1M | ↑ 17.37% |
Investing Cash Flow | -269.0M | ↓ 84.63% |
Financing Cash Flow | -409.1M | ↓ 175.62% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 798.9M | ↑ 15.27% |
Investing Cash Flow | -394.5M | ↑ 46.68% |
Financing Cash Flow | -479.1M | ↑ 17.11% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 776.4M | ↓ 2.82% |
Investing Cash Flow | -155.3M | ↓ 60.63% |
Financing Cash Flow | -293.7M | ↓ 38.69% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 899.6M | ↑ 15.87% |
Investing Cash Flow | -1.0B | ↑ 548.85% |
Financing Cash Flow | 528.1M | ↓ 279.77% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 778.5M | ↓ 13.47% |
Investing Cash Flow | -5.2B | ↑ 417.25% |
Financing Cash Flow | 4.0B | ↑ 651.89% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↑ 63.39% |
Investing Cash Flow | -446.2M | ↓ 91.44% |
Financing Cash Flow | -529.5M | ↓ 113.34% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 209.0M | ↑ 17.57% |
Investing Cash Flow | -37.3M | ↑ 269.52% |
Financing Cash Flow | -270.8M | ↑ 9.81% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 303.0M | ↑ 45.01% |
Investing Cash Flow | -89.2M | ↑ 139.09% |
Financing Cash Flow | 10.8M | ↓ 103.98% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 418.0M | ↑ 37.93% |
Investing Cash Flow | 4.6M | ↓ 105.16% |
Financing Cash Flow | -289.1M | ↓ 2782.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 342.0M | ↓ 18.19% |
Investing Cash Flow | -324.4M | ↓ 7148.63% |
Financing Cash Flow | 19.6M | ↓ 106.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 320.7M | ↓ 6.22% |
Investing Cash Flow | -4.8M | ↓ 98.51% |
Financing Cash Flow | -29.8M | ↓ 252.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 296.8M | ↓ 7.47% |
Investing Cash Flow | -85.7M | ↑ 1678.08% |
Financing Cash Flow | -96.7M | ↑ 224.52% |
Sell
Neutral
Buy
Jazz Pharmaceuticals Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Jazz Pharmaceuticals Plc | -7.65% | -7.97% | 1.78% | -7.25% | -21.95% |
![]() Moderna, Inc. | -12.64% | -32.32% | -18.59% | 40.95% | 434.62% |
![]() Regeneron Pharmaceuticals, Inc. | 0.2% | 0.68% | 18.02% | 45.57% | 106.06% |
![]() Novo Nordisk A/s | -2.18% | 18.08% | 84.58% | 165.14% | 289.05% |
![]() Seagen, Inc. | 3.05% | 4.69% | 54.33% | 11.57% | 175.61% |
![]() Vertex Pharmaceuticals Incorporated | -0.55% | 11.62% | 19.58% | 30.6% | 81.41% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Jazz Pharmaceuticals Plc | NA | NA | 3.99 | 18.59 | -0.03 | 0.06 | 0.0 | 55.61 |
![]() Moderna, Inc. | 34.67 | 34.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.3 | 43.3 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.94 | 26.94 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Jazz Pharmaceuticals Plc | Buy | $8.4B | -21.95% | NA | -2.3% |
![]() Moderna, Inc. | Buy | $37.3B | 434.62% | 34.67 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 106.06% | 21.73 | 33.93% |
![]() Novo Nordisk A/s | Buy | $410.6B | 289.05% | 43.3 | 33.4% |
![]() Seagen, Inc. | Hold | $40.6B | 175.61% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.2B | 81.41% | 26.94 | 35.4% |
BlackRock Inc
Vanguard Group Inc
State Street Corporation
LSV Asset Management
Wellington Management Company LLP
JPMorgan Chase & Co
Jazz Pharmaceuticals Plc’s price-to-earnings ratio stands at None
Read Morejazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Organization | Jazz Pharmaceuticals Plc |
Employees | 2800 |
CEO | Mr. Bruce C. Cozadd |
Industry | Health Technology |
Smartsheet Inc.
$131.03
-0.15%
Ishares Msci Min Vol Global Etf
$131.03
-0.15%
Dimensional International Co
$131.03
-0.15%
Allegro Microsystems, Inc.
$131.03
-0.15%
Endeavor Group Holdings, Inc.
$131.03
-0.15%
Ishares 0-5 Year Investment Grade Corporate Bond Etf
$131.03
-0.15%
Allison Transmission Holdings, Inc.
$131.03
-0.15%
Immunocore Holdings Plc-adr
$131.03
-0.15%
Elbit Systems Ltd.
$131.03
-0.15%